Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder
Key facts
- Who runs it
- Philadelphia College of Osteopathic Medicine
- Where
- Atlantic City and Philadelphia, United StatesSee the 5 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 340 people enrolled
- Started
- 15 Jul 2020
- Ended
- 30 Jun 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Psychosocial treatment
- Record updated
- 31 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Adults (≥18 years)
- Be deemed eligible for buprenorphine treatment for OUD by the FQHC treatment provider and agree to engage in this treatment
- Not require an inpatient level of care as determined by the healthcare provider
- Be capable of providing valid contact information and informed consent; and
- Permit the research team to use and disclose their protected health information (PHI)
Who cannot take part
- Individuals who are intoxicated, cognitively impaired, or psychiatrically unstable at baseline will not be included; however, they may subsequently be included if the disqualifying condition subsides
- Withdrawal. Moderate OUD severity is denoted by the presence of 4 or 5 of these symptoms and severe OUD is denoted by 6 or more symptoms. Patients will be excluded from the study if their SUD is primarily for a different substance, or their co-morbid psychiatric needs indicate enhanced needs
- DSM 5 criteria for OUD include:
- Taking opioids in larger amounts or longer than intended
- Failed efforts to quit or cut back
- Spending a lot of time obtaining the opioid
- Craving or urges to use
- Repeated inability to carry out major work, school, or home obligations
- Continued use despite persistent or recurring interpersonal problems worsened by opioid use
- Stopping or reducing important social, recreational activities due to opioid use
- Recurrent use of opioids in physically hazardous situations
- Continued opioid use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance
- Tolerance; and
Where in United States
- AtlantiCareAtlantic City, United States
- Berks Community Health CenterPhiladelphia, United States
- Care ClinicPhiladelphia, United States
- Delaware Valley Community HealthPhiladelphia, United States
- Philadelphia FIGHTPhiladelphia, United States
About the trial
What the trial wants to find out
Current clinical guidelines for medication assisted treatment (MAT) of opioid use disorder (OUD) recommend that treatment include a psychosocial component to help address psychological factors related to addiction. However, a knowledge gap exists regarding the most effective forms of psychosocial intervention and what interventions are most effective for different types of patients. This gap represents a significant barrier to the widespread implementation of effective office-based opioid treatment (OBOT) with buprenorphine, which is important to improving opioid treatment and responding to the critical needs of individuals living with OUD. The overarching goal of this patient-centered research is to address the diverse needs and preferences of OUD patients in regards to psychosocial approaches and to overcome the "one-size-fits-all" strategies that are typically used to treat OUD. Importantly, investigators arrived at this goal, in part, through collaboration and consultation with former patients who have received different types of treatments for OUD. In this manner, patients provided important insight to inform the selection of interventions to be evaluated, patient characteristics that may differentially impact the effects of the interventions, and the patient outcomes to be examined.
The 4 groups in the trial
- Treatment as usualNo study treatment, for comparison
Those randomized to treatment as usual will receive standard treatment from one of four FQHC sites.
- Office based CBTExisting treatment, for comparison
Those randomized to Cognitive Behavioral Treatment will receive cognitive behavioral treatment (CBT) along with standard treatment from the FQHC.
Treatment: Psychosocial treatment
- CRS/CPSExisting treatment, for comparison
Those randomized to certified recovery specialist(CRS)/peer support specialist(CPS) will receive a CRS/CPS along with standard treatment from the FQHC.
Treatment: Psychosocial treatment
- CBT+CRS/CPSExisting treatment, for comparison
Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with office-based CBT and a CRS.
Treatment: Psychosocial treatment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Identifying Optimal Psychosocial Interventions for Patients Receiving Office-Based Buprenorphine
- Publications
- Adjunctive Psychosocial Interventions and Opioid Abstinence Among Patients Receiving Buprenorphine: A Randomized Clinical Trial.JAMA network open, 2026
- Prevalence and predictors of suicidality among adults initiating office-based buprenorphine.Addiction science & clinical practice, 2023
- Record updated
- 31 July 2025